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Hepatocellular carcinoma is the most common primary malig-
nancy of the liver. HepG2 represents a pure cell line of human
liver carcinoma. The purpose of the current study was character-
ization of exosomes derived from HepG2 cells line.
Exosomes were isolated from HepG2 cell culture supernatant
by a series of subsequent centrifugation steps. Morphology of
exosomes was determined by electron microscopy. To character-
ize HepG2 cell derived exosomes we also examined the presence
of the ER-residing protein Calnexin by Western blot. Data showed
that Calnexin was absent in exosomes. Taken together, these
results indicate that vesicles obtained from cell-free supernatants
of HepG2 cells exhibit properties of exosomes.
Proteome analysis was performed for proteins commonly
expressed in HepG2 cells such as cytochromes P450 that serve
important roles in the cellular detoxification process and drug
metabolism. We identified members of protein families cyto-
chromes P450 CYP1A1 b CYP1A2 in both HepG2 cells and
exosomes.
Thus, hepatocyte-derived exosome population should be use-
ful in our further understanding of the hepatic function and in
the identification of components that may serve as biomarkers
for hepatic alterations. These tumor-derived extracellular vesicles
represent a mediator of the tumor microenvironment, and their
presence in the peripheral circulation may serve as a surrogate
for tumor biopsies, enabling real-time diagnosis and disease
monitoring.
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Background: TP53 dysfunction is implicated in lymphomagen-
esis and disease progression. Information about the frequency
and spectrum of TP53 mutations in the Russian pathients with
diffuse large B-cell lymphoma (DLBCL) in the current version of
the IARC TP53 Mutation Database R17 is not represented. The goal
of this work was to study the frequency, spectrum and functional
significance of TP53 mutations in Russian patients with DLBCL.
Material and methods: At the present time the pilot group of 14
patients were included in the study. Diagnosis was assessed
according to the criteria of the WHO classification system.
Genomic DNA was isolated from formalin-fixed, paraffin embed-
ded tissue blocks. Direct sequence analysis of gene TP53 was
performed according to the IARC protocol, 2010 update.
Results: In two patients were identified single nucleotide sub-
stitutions that are not described in the current version of the
PubMed database. All of mutations occurred in the DNA-binding
domain of p53. The nonsense mutation Arg196Ter was detected
in one patient. Previously it was shown that formation of this
premature stop codon might activate the nonsense-mediated
RNA decay pathway. The second patient had two missense muta-
tions – Leu130Phe and Arg156Cys. The first of them leads to p53
inactivation according to the analysis of the functional impor-
tance of amino acid substitutions using service PolyPhen-2.
Conclusion: We detected TP53 mutation in 14% cases. The
mutational rate in our study is in good agreement with other
studies where the frequency of the TP53 mutations in patients
with DLBCL ranged mostly from 13% to 23%.
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Nowadays the term ‘‘epigenetics” is described as regulation of
gene expression persisting from one cell division to the next,
despite a lack of changes in the underlying DNA sequence. The
‘‘epigenome” refers to different epigenetic states of a cell recog-
nized as heritable environment influence on genome. The main
epigenetic phenomena in mammals are DNA methylation and
histone modifications, which are tightly interdependent. Many
authors classify microRNA regulation as a third epigenetic phe-
nomenon. Moreover, recently the discussion has been open that
many different factors modifying DNA conformation represent
a new class of epigenetic agents. In response to various environ-
mental stimuli, cells produce different epigenetic changes that
determine either an active or a repressed chromatin state.
Epigenetic perturbations have been shown to associate with
exposure to a range of drugs and toxicants, including non-
genotoxic carcinogens. Consequently, on one hand, potential
impact of epigenomics on drug development is under considera-
tion as even well-known pharmacological drugs were shown to
cause epigenetic changes that may be beneficial or hazardous.
In particular, epigenetic effects were described for synthetic
estrogens and contraceptives, beta-blockers and fluoroquinolone
antibiotics, neuroleptics and anesthetics, chemotherapeutics and
statins. Drug influence on gene silencing might have some
therapeutic advantage in addition to the unfavourable effects.
In particular, valproate, hydralazine and procainamide might be
utilized to induce gene expression in cancers, where activation
of a methylated gene might be of benefit. Screening of xenobiotics
for epigenetic activity might identify new potential drugs for
some specific diseases.
On the other hand, epigenetic aspects of drug safety are inves-
tigated intensively. Many recent reviews in this field of research
were devoted to the test elaboration for revealing different
short-term and longer-lasting epigenetic changes modifying gene
expression. Most of the short-term epigenetic screening tests are
66 EJC SUPPLEMENTS 13 (2015) 1–75
